PopVax's experimental work and clinical dose production is based at the RNA Foundry, PopVax's integrated R&D and GMP-capable clinical dose production facility in Hyderabad, which is fully equipped to advance novel RNA medicines from concept to clinic in months, not years.
We are open to collaborating with academic and industrial partners to develop their RNA vaccine and therapeutic sequences into drug candidates atop our mRNA platform, including our LNP formulations based on our novel ionizable lipids. We can then help rapidly advance these novel RNA medicines into first-in-human trials by manufacturing clinical doses at the RNA Foundry in Phase I-appropriate GMP conditions – if this is of interest, email foundry [at] popvax.com
We are also interested in working with patients and clinicians to develop and manufacture personalized RNA medicines, in particular cancer immunotherapies, at the RNA Foundry.
Our R&D lab has comprehensive capabilities in molecular biology, cell biology, and immunology, including high-throughput functional assays, as well as in lipid synthesis, LNP formulation & optimization, and mRNA-LNP analytical testing.
The RNA Foundry's fast-turnaround GMP-capable production process, which is a critical plank of our full-stack strategy, goes from plasmid all the way to finished mRNA-LNP product, including the synthesis of our novel ionizable lipids, the key excipient of our formulations, in GMP conditions.
We have developed and operationalized extensive analytical methods for quality control (QC) of our process and mRNA-LNP products, which we execute primarily at our on-site QC lab.
Our experienced production and QC teams have cumulatively manufactured and tested billions of doses vaccines and biologics in their prior roles, and we are fully prepared to scale up our in-house production of mRNA-LNP to accomodate our rapidly-expanding slate of programs.
If the challenge of helping operate, adapt, and optimize the RNA Foundry appeals to you, whether in production, engineering, QC, or QA, join us!